ProMIS Neurosciences Q1 net loss $8.2M; PRECISE-AD interim analysis expected early Q3 2026

ProMIS Neurosciences Inc.

• Net loss of $8.2M for Q1 2026, vs $7.3M in Q1 2025; cash & equivalents $63.8M as of March 31.
• Closed $75.5M PIPE in Feb 2026; up to $100M additional from warrant exercises; funds operations through 2027.
• PRECISE-AD Phase 1b fully enrolled (144 participants); blinded 6-month interim analysis anticipated early Q3 2026.
• Unblinded 12-month top-line data expected early 2027; subcutaneous formulation development accelerated.
• Lead candidate PMN310 selectively targets toxic amyloid-beta oligomers, aiming to improve safety vs plaque-directed antibodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.